DermTech is a molecular diagnostic company developing and marketing non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Co.'s focus is skin cancer. Co. provides the DermTech Melanoma Test for the early detection of melanoma and is developing a product for non-melanoma skin cancer. Co. is also working on products to assess precancerous genomic changes associated with sun UV exposure to the skin. Co. has additional skin cancer product offerings, including for non-melanoma skin cancers (basal cell and squamous cell cancers), under development.
|
Free DMTK Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (3.20 out of 4) 40th percentile
(ranked lower than approx. 60% of all stocks covered)
Analysts' Target Price: DMTK Stock Forecast Based on Zacks ABR data; powered by Xignite |